ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +16.7% ·
share flow +30.0% ·
net new positions +14.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.87M | $3.69B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | — |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | — |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.33M | +374.5% | $25.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.33M | +374.5% | $25.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 360.73K | -25.2% | $6.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 342.42K | +2348.6% | $6.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 342.42K | +2348.6% | $6.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 95.09K | +15.8% | $1.84M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 69.20K | -65.4% | $1.34M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 30.30K | New | $587,614 | 0.0% | New | 1 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 25.02K | — | $485,196 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $587,614 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 900 sh · $98,687
Officer · 300 sh · $33,155
Officer · 3.32K sh · $371,886
Officer · 2.48K sh · $279,154
Officer · 3.63K sh · $384,963
Officer · 10.43K sh · $1.12M
Officer · 14.70K sh · $1.59M
Officer · 10.20K sh · $1.11M
Officer · 9.19K sh · $1.01M
Officer · 3.85K sh · $427,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗